Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | IGF1R | P08069 | 1/20 | 0.77 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.77 |
| ▸ | SYK | P43405 | 1/20 | 0.77 |
| ▸ | BMX | P51813 | 1/20 | 0.77 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.55 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777946 | 0.87 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| Anilinopyrimidine1 SCHEMBL676556 | 0.87 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL27075735 | 0.78 | AURKA (0.66) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL3694508 | 0.77 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL4237476 | 0.77 | AURKA (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL3694510 | 0.74 | AURKA (0.85) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL4237478 | 0.74 | AURKA (0.85) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL2158639 | 0.74 | AURKA (0.64) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL242230 | 0.71 | EGFR (1.00) | AURKALCKIGF1REIF2AK2SYK | |
| SCHEMBL19966813 | 0.71 | ABL1 (0.59) | AURKALCKIGF1REIF2AK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957484-B2 | Methods for promoting cell reprogramming | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |